Interleukin-6 Immunology in Macrophage Activation Syndrome Related to Neuroimmunological Diseases-Reference-Cited by-同舟云学术

Interleukin-6 Immunology in Macrophage Activation Syndrome Related to Neuroimmunological Diseases

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Nomura Taichi¹,Niino Masaaki²,Odani Toshio³,Naganuma Ryoji¹,Amino Itaru¹,Miyazaki Yusei¹,Akimoto Sachiko¹,Tanei Zen-ichi⁴,Kimura Taichi⁵,Minami Naoya¹,Kikuchi Seiji¹

Affiliation:

1. Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan

2. Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Japan

3. Department of Rheumatology, National Hospital Organization Hokkaido Medical Center, Japan

4. Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Japan

5. Department of Pathology, National Hospital Organization Hokkaido Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3757-24/_pdf

Reference19 articles.

1. 1. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12: 259-268, 2016.

2. 2. Strippoli R, Carvello F, Scianaro R, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 64: 1680-1688, 2012.

3. 3. Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 36: 135-141, 2011.

4. 4. Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord 27: 565-568, 2017.

5. 5. Uzawa A, Akamine H, Kojima Y, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol 358: 577634, 2021.